Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.92 |
| ▸ | GSK3B | P49841 | 1/20 | 0.92 |
| ▸ | CCR6 | P51684 | 1/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL17338087 | 1.00 | — | — | |
| SCHEMBL7021498 | 0.96 | — | — | |
| SCHEMBL693917 | 0.96 | GSK3B (1.00) | GSK3AGSK3BCCR6ALDH1A1BCHE | |
| SCHEMBL33524954 | 0.96 | — | — | |
| SCHEMBL10990 | 0.96 | — | — | |
| SCHEMBL715867 | 0.96 | GSK3B (1.00) | GSK3AGSK3BCCR6ALDH1A1BCHE | |
| SCHEMBL6437568 | 0.92 | — | — | |
| SCHEMBL1768562 | 0.92 | — | — | |
| SCHEMBL6513348 | 0.92 | GSK3A (0.92) | GSK3AGSK3BCCR6ALDH1A1BCHE | |
| SCHEMBL16428717 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265786-A | Microtubule-associated protein Tau (MAPT) iRNA pharmaceutical compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-06-28 | — | — | CN | claimed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | claimed |
| US-20240200077-A1 | STEAROYL-COA DESATURASE 5 (SCD5) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| CN-118176300-A | Huntington (HTT) iRNA agent compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-06-11 | — | — | CN | claimed |
| WO-2024114776-A1 | BICYCLIC ABASIC NUCLEIC ACID ANALOGS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | 上海舶望制药有限公司 | 2024-06-06 | — | — | WO | claimed |
| EP-4373937-A1 | METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| EP-4363587-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-08 | — | — | EP | claimed |
| EP-4363588-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals Inc. (US) | 2024-05-08 | — | — | EP | claimed |
| EP-4359522-A1 | IRNA COMPOSITIONS AND METHODS FOR SILENCING FILAMIN A (FLNA) | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| EP-3790970-A1 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals Inc. (US) | 2021-03-17 | — | — | EP | claimed |
| CN-112400018-A | Extrahepatic delivery | 阿尔尼拉姆医药品有限公司 | 2021-02-23 | — | — | CN | claimed |
| WO-2021030522-A1 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | claimed |
| EP-3166406-B1 | CYTOKINE-CHITOSAN BIOCONJUGATES AND METHODS OF USING THE SAME | UNIV ARKANSAS (US) | 2020-08-05 | — | — | EP | claimed |
| WO-2020132227-A2 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | claimed |
| WO-2020069055-A1 | TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | WO | claimed |
| WO-2019217459-A1 | EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | claimed |
| EP-3166406-A1 | CYTOKINE-CHITOSAN BIOCONJUGATES AND METHODS OF USING THE SAME | The Board of Trustees of the University of Arkansas (US) | 2017-05-17 | — | — | EP | claimed |
| US-20170106092-A1 | CYTOKINE-CHITOSAN BIOCONJUGATES AND METHODS OF USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2017-04-20 | — | — | US | claimed |
| WO-2015184445-A1 | CYTOKINE-CHITOSAN BIOCONJUGATES AND METHODS OF USE THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2015-12-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | CHI3L1, CHIA, CHI3L2 | GSK3A 733/4885GSK3B 1166/4885CCR6 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.